Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Spotlight on Trastuzumab in Metastatic Breast Cancer Overexpressing HER2

Spotlight on Trastuzumab in Metastatic Breast Cancer Overexpressing HER2 Trastuzumab is a humanized monoclonal antibody developed to target the HER2 receptor which is over-expressed by some cancer cells, including 25 to 30% of breast cancers. Binding with high affinity to the extracellular domain of HER2, trastuzumab inhibits the proliferation of tumor cells that overexpress HER2. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Spotlight on Trastuzumab in Metastatic Breast Cancer Overexpressing HER2

American Journal of Cancer , Volume 1 (3) – Aug 9, 2012

Loading next page...
 
/lp/springer-journals/spotlight-on-trastuzumab-in-metastatic-breast-cancer-overexpressing-8sEhbkWKoH
Publisher
Springer Journals
Copyright
Copyright © 2002 by Adis International Limited
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200201030-00006
Publisher site
See Article on Publisher Site

Abstract

Trastuzumab is a humanized monoclonal antibody developed to target the HER2 receptor which is over-expressed by some cancer cells, including 25 to 30% of breast cancers. Binding with high affinity to the extracellular domain of HER2, trastuzumab inhibits the proliferation of tumor cells that overexpress HER2.

Journal

American Journal of CancerSpringer Journals

Published: Aug 9, 2012

References